Clinical Trial Update: Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, tolerability, and immunogenicity of three dose levels of the ACAM3000 Smallpox Vaccine. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• ACAM3000 Smallpox Vaccine (ACAM3000)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Smallpox | Phase 2 | Status: COMPLETED